Community-based trial of a peripheral prism visual field expansion device for hemianopia
Community-based trial of a peripheral prism visual field expansion device for hemianopia
复制标题
DOI：
10.1001/archopht.126.5.657
复制
发表时间：
2008-05-01
影响因子：
--
通讯作者：
Peli, Eli
中科院分区：
文献类型：
--
作者：
Bowers, Alex R.;Keeney, Karen;Peli, Eli
目的：为了确定周边棱镜眼镜，一种新的视野扩大装置，偏盲，在一个大规模的，以社区为基础的，多中心的研究与长期follow-up.Methods：43名参与者homeopathy偏盲的一般流动性的功能效用与临时压力菲涅尔周边棱镜段40棱镜屈光度。第6周，在办公室进行随访问卷调查，评估活动的功能益处。继续佩戴棱镜的参与者在中位数12个月后再次接受电话采访。主要结果的措施包括临床成功（临床决定继续磨损）和5点评级的棱镜帮助避障时walking.Results：32名参与者（74%）继续棱镜磨损在第6周，和20（47%）仍然穿着棱镜后12个月（中位数时间，每天8小时）。这些参与者认为棱镜眼镜对避障非常有帮助，并报告了在各种移动情况下避障的显着好处。成功率各不相同的诊所组（27%-81%），在诊所，适合更多的patients.Conclusion：我们的研究结果表明，周边棱镜眼镜的功能实用性作为一个一般的流动援助偏盲患者。
Objective: To determine the functional utility for general mobility of peripheral prism glasses, a novel visual field expansion device for hemianopia, in a large-scale, community-based, multicenter study with long-term follow-up.Methods: Forty-three participants with homonymous hemianopia were fitted with temporary press-on Fresnel peripheral prism segments of 40 prism diopters. Followup questionnaires evaluating functional benefits for mobility were administered in the office at week 6. Participants who continued wearing the prisms were interviewed again by telephone after a median of 12 months. Primary outcome measures included clinical success ( a clinical decision to continue wear) and 5-point ratings of prism helpfulness for obstacle avoidance when walking.Results: Thirty-two participants (74%) continued prism wear at week 6, and 20 (47%) were still wearing the prisms after 12 months ( median time, 8 hours per day). These participants rated the prism glasses as very helpful for obstacle avoidance and reported significant benefits for obstacle avoidance in a variety of mobility situations. Success rates varied among clinic groups (27%-81%), with higher rates at the clinics that fitted more patients.Conclusion: Our results demonstrate the functional utility of peripheral prism glasses as a general mobility aid for patients with hemianopia.